ATANASIO
PANDIELLA ALONSO
Investigador
Institute of Oncology Ljubljana
Liubliana, EsloveniaPublications in collaboration with researchers from Institute of Oncology Ljubljana (11)
2017
-
Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs
Molecular Diagnosis and Therapy, Vol. 21, Núm. 3, pp. 337-343
2016
-
Circulating DNA and survival in solid tumors
Cancer Epidemiology Biomarkers and Prevention, Vol. 25, Núm. 2, pp. 399-406
-
In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: Role of mitotic kinases
Oncotarget, Vol. 7, Núm. 16, pp. 22865-22872
-
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer
Breast Cancer Research and Treatment, Vol. 156, Núm. 1
2015
-
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: Systematic review and meta-analyses
Oncotarget, Vol. 6, Núm. 37, pp. 39538-39549
2014
-
Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: Systematic review and meta-analysis
PLoS ONE, Vol. 9, Núm. 4
-
Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors
Cancer and Metastasis Reviews, Vol. 33, Núm. 1, pp. 295-307
-
Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis
Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1048-1055
2013
-
HER3 overexpression and survival in solid tumors: A meta-analysis
Journal of the National Cancer Institute, Vol. 105, Núm. 4, pp. 266-273
-
The evolving landscape of protein kinases in breast cancer: Clinical implications
Cancer Treatment Reviews, Vol. 39, Núm. 1, pp. 68-76
2011
-
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2543-2549